HUAHONG

Founded in December 2010 and based in Tianjin Pilot Free Trade Zone, Tianjin Huahong Technology Co., Ltd. has a registered capital of 50.169 million RMB. It focuses on R&D, production and sales of peripheral blood collection devices and insulin pen needles; its subsidiary specializes in minimally invasive surgical instruments.

A national high-tech enterprise and national "Little Giant" enterprise (2021, 2024), it’s listed on NEEQ (Stock Code: 873804). Its peripheral blood collection needles hold ~10% global and over 30% domestic market share. Certified by ISO 13485, FDA, etc., it cooperates with Abbott, Johnson & Johnson. Guided by its values, it strives to lead in medical device segments.